Non Small Cell Lung Carcinoma Clinical Trial
— ZPACT| Verified date | September 2017 |
| Source | Novartis |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study will evaluate the effects of an investigational drug in combination with chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. This study will measure the effects of this combination on progression of lung cancer, cancer response to treatments, and development of cancer-related bone lesions.
| Status | Completed |
| Enrollment | 250 |
| Est. completion date | October 2007 |
| Est. primary completion date | October 2007 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Male or Female patients at least of 18 years old - Patients with diagnosed non-small cell lung cancer that cannot be treated by surgery - Women must not be pregnant or attempting to become pregnant - Able and willing to sign informed consent Exclusion Criteria: - Patients with cancer that has spread to the bone - Patients with cancer that has spread to the brain who are receiving treatment - Patients with kidney disease - Patients treated with other investigational drugs |
| Country | Name | City | State |
|---|---|---|---|
| United States | New Mexico Oncology Hematology Consultants, Ltd. | Albuquerque | New Mexico |
| United States | Emory University | Atlanta | Georgia |
| United States | Peachtree Hematology & Oncology | Atlanta | Georgia |
| United States | Barberton Citizens Hospital-Cancer Center | Barberton | Ohio |
| United States | Hematology/Oncology Clinic | Baton Rouge | Louisiana |
| United States | Mary Bird Perkins Cancer Center | Baton Rouge | Louisiana |
| United States | Engracio Cortes, MD | Bayside | New York |
| United States | Odyssey Research | Belle Haven | Virginia |
| United States | Oncology Care Associates | Bethesda | Maryland |
| United States | Lynn Regional Cancer Center | Boca Raton | Florida |
| United States | Charleston Cancer Center | Charleston | South Carolina |
| United States | Charleston Hematology Oncology | Charleston | South Carolina |
| United States | Presbyterian Hospital | Charlotte | North Carolina |
| United States | St. Louis Cancer Care | Chesterfield | Missouri |
| United States | Advocate Illinois Masonic Medical Center Creticos Cancer Center | Chicago | Illinois |
| United States | Cancer Center of Colorado Springs | Colorado Springs | Colorado |
| United States | Liberty Hematology-Oncology | Columbia | South Carolina |
| United States | Cancer Specialists of South Texas | Corpus Christi | Texas |
| United States | Dayton Clinical Oncology Program | Dayton | Ohio |
| United States | Karmanos Cancer Institute | Detroit | Michigan |
| United States | East Orange VA Medical System | East Orange | New Jersey |
| United States | NorthBay Cancer Center | Fairfield | California |
| United States | San Juan Regional Cancer Ctr. | Farmington | New Mexico |
| United States | The Jones Clinic | Germantown | Tennessee |
| United States | Arena Oncology Assoc. | Great Neck | New York |
| United States | Southern Oncology Research | Grifton | North Carolina |
| United States | Kaiser Foundation Hospital | Honolulu | Hawaii |
| United States | Straub Clinic & Hospital | Honolulu | Hawaii |
| United States | Clinical Research Consultants | Hoover | Alabama |
| United States | Howell Office Plaza | Howell | New Jersey |
| United States | New Hope Cancer Centers | Hudson | Florida |
| United States | Central Indiana Cancer Centers | Indianapolis | Indiana |
| United States | NEA Clinic | Jonesboro | Arkansas |
| United States | Kalamazoo Hematology & Oncology | Kalamazoo | Michigan |
| United States | Oceola Cancer Center | Kissimmee | Florida |
| United States | Knoxville Cancer Center | Knoxville | Tennessee |
| United States | Oncology Institute of Greater Lafayette | Lafayette | Indiana |
| United States | Nevada Cancer Center | Las Vegas | Nevada |
| United States | Southern Nevada Cancer Research Foundation | Las Vegas | Nevada |
| United States | Kansas City Cancer Ctr. South | Lenexa | Kansas |
| United States | Southeast Nebraska Cancer Center | Lincoln | Nebraska |
| United States | UCLA | Los Angeles | California |
| United States | Atlantic Hem Onc Associates, LLC | Manasquan | New Jersey |
| United States | Hematology Oncology Associates | Medford | Oregon |
| United States | VA Medical Center | Miami | Florida |
| United States | Innovative Medical Research of South Florida, Inc. | Miami Shores | Florida |
| United States | Clinical Trials and Research Associates, Inc. | Montebello | California |
| United States | West Virginia University | Morgantown | West Virginia |
| United States | Hematology/Oncology Assoc. of South Jersey | Mount Holly | New Jersey |
| United States | Community Hospital, Cancer Research Dept. | Munster | Indiana |
| United States | NCH Healthcare System Oncology Research | Naples | Florida |
| United States | Cancer Specialists of Oklahoma | Oklahoma City | Oklahoma |
| United States | Med. Oncology Care Associates | Orange | California |
| United States | Metcare Oncology | Ormond Beach | Florida |
| United States | Hematology-Oncology Associates | Pensacola | Florida |
| United States | Berkshire Hematology Oncology PC | Pittsfield | Massachusetts |
| United States | James P. Wilmot Cancer Center | Rochester | New York |
| United States | OSF Center for Cancer Care | Rockford | Illinois |
| United States | Park Nicollett Institute | Saint Louis Park | Minnesota |
| United States | Cancer Center of Santa Barbara | Santa Barbara | California |
| United States | New Mexico Cancer Care Associates | Santa Fe | New Mexico |
| United States | Maine Center for Cancer Medicine | Scarborough | Maine |
| United States | Odyssey Research | Scottsbluff | Nebraska |
| United States | AMIT SHAH Medical Group | Sebring | Florida |
| United States | LSU Health Sciences Center | Shreveport | Louisiana |
| United States | Northern Indiana Oncology Associates | South Bend | Indiana |
| United States | Highlands Oncology Group | Springdale | Arkansas |
| United States | Springfield Clinic, LLP | Springfield | Illinois |
| United States | Santee Hematology/Oncology | Sumter | South Carolina |
| United States | SUNY Upstate Medical University | Syracuse | New York |
| United States | Syracuse VA Medical Center | Syracuse | New York |
| United States | Northern Hematology-Oncology | Thornton | Colorado |
| United States | Mitchell Folbe, MD, PC | Troy | Michigan |
| United States | Arizona Oncology Assoc. | Tucson | Arizona |
| United States | Blood and Cancer Center of East Texas | Tyler | Texas |
| United States | Tyler Hematology Oncology, PA | Tyler | Texas |
| United States | Cancer Institute of New Jersey at Cooper University Hospital | Voorhees | New Jersey |
| United States | Cedar Valley Medical Specialists | Waterloo | Iowa |
| United States | Masoom Kandahari, MD | Woodbridge | Virginia |
| United States | Forum Health Cancer CareCenter | Youngstown | Ohio |
| Lead Sponsor | Collaborator |
|---|---|
| Novartis Pharmaceuticals |
United States,
Pandya KJ, Gajra A, Warsi GM, Argonza-Aviles E, Ericson SG, Wozniak AJ. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer — View Citation
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01229150 -
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
|
Phase 2 | |
| Terminated |
NCT00592007 -
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00199758 -
Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01999738 -
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01941316 -
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00111839 -
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
|
Phase 2 | |
| Completed |
NCT00181532 -
Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC
|
Phase 2 | |
| Completed |
NCT00890903 -
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)
|
N/A | |
| Completed |
NCT00864266 -
Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer
|
N/A | |
| Completed |
NCT00635791 -
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT00727350 -
Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.
|
Phase 2 | |
| Completed |
NCT01209520 -
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
|
N/A | |
| Active, not recruiting |
NCT00759382 -
Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
|
||
| Completed |
NCT00087711 -
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT00252798 -
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT02938624 -
Anti PD-1 Neo-adjuvant Treatment for NSCLC
|
Phase 1 | |
| Terminated |
NCT00661011 -
Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy
|
Phase 2 | |
| Completed |
NCT00608868 -
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
|
Phase 4 | |
| Terminated |
NCT00234468 -
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
|
Phase 3 | |
| Completed |
NCT00193921 -
Chemoradiotherapy in Patients With Localised Lung Cancer
|
Phase 2 |